EUVIMED · CrossrefZeitschrift
Future Prescriber
ISSN 1468-9871 · Wiley
Neueste Artikel
Primary prevention for all?
Liraglutide: a new option in the management of type 2 diabetes
Ruxolitinib: JAK2 inhibitor for treatment of myelofibrosis
Canagliflozin: SGLT2 inhibitor for treating type 2 diabetes
Apremilast for the treatment of psoriasis and psoriatic arthritis
IMS Institute Global Use of Medicines: Outlook Through 2016
COPD: new treatment strategies
Role and cost effectiveness of bariatric surgery in T2DM
Lurasidone: new development for the treatment of psychosis
Treatment of rheumatoid arthritis: current and future
Promising new drugs and drug targets for HIV treatment
Sunovion: innovative medicines for areas of unmet clinical need
Rituximab in advanced rheumatoid arthritis
Sorafenib: advances in targeted therapy for renal cell carcinoma
Rimonabant in the management of cardiovascular risk
The evolution of tyrosine‐kinase‐targeted cancer therapies
Methylnaltrexone for opioid induced constipation
Alitretinoin in the treatment of hand eczema
An overview of the clinical trial data presented at the 44th American Society of Clinical Oncology Annual Meeting (ASCO) and the 9th Annual European Congress of Rheumatology (EULAR)
Use of unlicensed drugs: what are the issues?
Trastuzumab: preparation and planning will avoid chaos
News round‐up
Anti‐TNF drugs in psoriasis and IBD ‐ Where are we going?
Aromatase inhibitors in preventing breast cancer recurrence
Improving CVD risk assessment with eGFR
Tigecycline: a novel broad spectrum antibiotic
Can NICE do its job?
Novel metabolic drugs for the management of type 2 diabetes
The role of interferon beta in multiple sclerosis management
Pegaptanib sodium for age-related macular degeneration
EUVIMED